VaxGen Inc.'s investigational vaccine for the prevention of HIV infection failed to hit primary or secondary endpoints in a Phase III trial conducted in Thailand. (BioWorld Today)
VaxGen Inc.'s investigational vaccine for the prevention of HIV infection failed to hit primary or secondary endpoints in a Phase III trial conducted in Thailand. (BioWorld Today)
Wall Street was unforgiving Tuesday, one day after Vertex Pharmaceuticals Inc. and partner Aventis SA voluntarily stopped a Phase IIb trial of a rheumatoid arthritis candidate on news that a related animal toxicology study turned up liver abnormalities. (BioWorld Today)
Wall Street was unforgiving Tuesday, one day after Vertex Pharmaceuticals Inc. and partner Aventis SA voluntarily stopped a Phase IIb trial of a rheumatoid arthritis candidate on news that a related animal toxicology study turned up liver abnormalities. (BioWorld Today)
